Please select the option that best describes you:
When is the best time to start denosumab in men with metastatic prostate cancer?
Should it be started at the initial diagnosis of bone mets?
Answer from: Medical Oncologist at Academic Institution
The data supporting the use of bone modifying agents (BMAs) such as denosumab or zoledronic acid are certainly the most solid for men with castration-resistant prostate cancer (i.e. progresion of disease through inital LHRH analog therapy) (Saad, JNCI 2004; 94: 1458–68; Fizzazi Lancet Onc...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I believe the question pertains to role of BMAs in castration sensitive prostrate cancer (CSPC). With regard to castration sensitive disease, the phase 3 trial which studied Zometa did not show decrease in SREs or improvement in OS (J Clin Oncol. 2014;32(11):1143. Epub 2014 Mar 3). Median follow up ...
Comments
Medical Oncologist at Stephen B. Strum, MD PC
An MD cannot use any anti-resorptive agent rationa...
An MD cannot use any anti-resorptive agent rationa...